Shatavari in Vitalux Women: Why Extract Identity Matters More Than Milligrams
TL;DR:
- Vitalux Women lists 100 mg of shatavari root extract per two capsules, but its active page does not display an extract ratio or shatavarin specification.
- Three recent human studies used 100, 500 and 300 mg/day of three differently defined extracts, measured with different marker and assay systems.
- A matching botanical name or milligram amount does not establish material identity; none of these ingredient studies proves an outcome for the finished Vitalux Women formula.
Vitalux Women lists 100 mg of shatavari root extract in its two-capsule daily serving. That number is a useful label fact, but it is not an extract identity: recent human studies have used markedly different shatavari preparations, and even a matching milligram amount does not make two materials equivalent.
Table of Contents
- What the Active Vitalux Women Label Confirms
- Why Botanical Milligrams Do Not Identify an Extract
- Three Human Studies, Three Different Shatavari Materials
- What the Study Comparison Can and Cannot Show
- A Five-Point Checklist for Reading Shatavari Research
- Shatavari Inside the Complete Vitalux Women Formula
- Frequently Asked Questions
Key Takeaways
| Evidence layer | What is verified | What remains unknown |
|---|---|---|
| Vitalux Women label | Shatavari root extract, 100 mg per two capsules | Extract ratio and shatavarin marker specification |
| 100 mg study | Named hydroethanolic extract with at least 5% Shatavarin IV | Whether Vitalux Women uses that proprietary material |
| 500 mg/day study | Full-spectrum extract with 5% total shatavarins by HPTLC | Equivalence to lower-dose or differently measured extracts |
| 300 mg/day study | 13:1 extract with more than 10% total shatavarins by HPLC | Transferability beyond its perimenopausal study population |
| Finished formula | Shatavari sits within a multi-ingredient botanical and micronutrient matrix | Finished-formula outcomes have not been established by these ingredient trials |
What the Active Vitalux Women Label Confirms
The active France product is listed as an adult food supplement with a suggested use of two capsules per day with water. Its botanical layer declares ashwagandha root extract 600 mg, maca root extract 180 mg, shatavari root extract 100 mg, Tribulus terrestris fruit extract 100 mg and saffron stigma extract 30 mg.
The official France label artwork also itemises zinc 15 mg, vitamin B6 3.5 mg, pantothenic acid 6 mg, riboflavin 1.4 mg, folate 200 micrograms, selenium 55 micrograms and vitamin B12 2.5 micrograms. Neither the active Shopify body nor that artwork names a specific allergen; that absence should not be read as an allergen-free guarantee. The artwork says the product contains plant extracts, is reserved for adults and is not recommended during pregnancy or breastfeeding.
For shatavari specifically, the public page gives the species, plant part and amount. It does not display an herb-to-extract ratio, extraction solvent, shatavarin percentage or analytical method. Those missing fields are decisive when comparing the label with research materials.
Why Botanical Milligrams Do Not Identify an Extract
A milligram value measures mass. It does not reveal how much raw root was concentrated into that mass, which solvent was used, or how much of a chosen marker the resulting powder contains. Two capsules can therefore list the same species and the same milligrams while delivering chemically different extracts.
Shatavari research frequently uses shatavarins, a group of steroidal saponins, as marker compounds. A specification such as “5% Shatavarin IV” is not the same as “5% total shatavarins”; neither is interchangeable with “more than 10% total shatavarins.” The method matters too: LC-MS, HPTLC and HPLC can define and quantify different targets under different laboratory procedures.
Three Human Studies, Three Different Shatavari Materials
Study 1: 100 mg/day of SheVari4
A 2026 randomised, double-blind, placebo-controlled study in 60 healthy women aged 40 to 55 used 100 mg/day for eight weeks. The test material was not generic shatavari: it was a proprietary water-ethanol root extract specified to contain at least 5% Shatavarin IV, with reported batch values of 6.687% to 7.094% by LC-MS.
The matching “100 mg” is superficially notable, but identity still cannot be inferred. The Vitalux Women page does not name SheVari4, the solvent system, or a Shatavarin IV specification. The study was also funded by the ingredient sponsor, two authors were sponsor employees, and outcomes were collected with a self-reported menopause rating scale. Those facts do not erase the trial; they define how cautiously it should be interpreted.
Study 2: 500 mg/day of Aspurus
A 2024 multicentre, randomised, placebo-controlled study enrolled 70 women and used 250 mg twice daily for 60 days, or 500 mg/day. Its Aspurus material was described as a full-spectrum root extract standardised to 5% total shatavarins by high-performance thin-layer chromatography.
This material differs from the first study in daily mass, marker definition and analytical method. The paper declared no competing interests, while its acknowledgements state that the ingredient producer supplied the investigational material and that outside support was provided for protocol documents and medical writing. Again, the useful reading is specific: the findings belong to Aspurus at the tested schedule.
Study 3: 300 mg/day of SRI-81
A 2025 randomised, double-blind, placebo-controlled study assigned 80 perimenopausal women to 300 mg/day or placebo for eight weeks. Here the shatavari material was a 13:1 root extract standardised to more than 10% total shatavarins by HPLC. The supplier provided the study extract, and 73 participants completed the study per protocol.
This third material is different again: a stated concentration ratio, a higher total-shatavarin specification, a distinct assay and a perimenopausal population. It is valuable evidence about that defined extract, not a bridge that automatically converts every shatavari label into the same result.
| Material | Daily amount | Identity marker | Design context | Transfer to Vitalux Women |
|---|---|---|---|---|
| SheVari4 | 100 mg | At least 5% Shatavarin IV; LC-MS verification | 60 healthy women across menopausal stages; 8 weeks | Not established despite the matching mass |
| Aspurus | 500 mg | 5% total shatavarins; HPTLC | 70 women; multicentre; 60 days | Not established |
| SRI-81 | 300 mg | 13:1; more than 10% total shatavarins; HPLC | 80 perimenopausal women; 8 weeks | Not established |
| Vitalux Women label | 100 mg | No ratio or shatavarin specification displayed | Multi-ingredient food supplement; not one of the trial materials | Label facts only |
What the Study Comparison Can and Cannot Show
The comparison shows that human shatavari research is becoming more specific. Investigators are naming extracts, reporting marker chemistry and describing study populations. It also shows why “clinically studied shatavari” is too broad a phrase unless the exact material on a product label is matched to the exact material in a paper.
These studies cannot establish an outcome for Vitalux Women. None tested the finished formula, and the active page does not provide enough extract-identification data to match its 100 mg ingredient to any of the three named preparations. The studies were short, involved 60 to 80 randomised participants, and used different populations and outcome instruments. Their results should remain attached to their own materials and designs.
That boundary is not a criticism of the label. It is simply the difference between ingredient disclosure and clinical equivalence. A transparent next step would be a supplier specification naming the extract ratio, marker compound, percentage and assay used for the Vitalux Women ingredient.
A Five-Point Checklist for Reading Shatavari Research
- Confirm species and plant part. Asparagus racemosus root is more precise than the word “shatavari” alone.
- Look for extraction details. Solvent and herb-to-extract ratio help describe how raw root became a concentrated powder.
- Read the marker literally. Shatavarin IV and total shatavarins are different specifications; record the assay beside the percentage.
- Compare the full daily schedule. 100 mg once daily, 250 mg twice daily and 300 mg once daily are three different exposures.
- Audit the study context. Population, duration, outcome measure, attrition, supplier involvement and author conflicts all affect portability.
Shatavari Inside the Complete Vitalux Women Formula
Vitalux Women is not a single-ingredient shatavari capsule. Its 100 mg root extract sits beside four other botanicals and a micronutrient layer. Research on isolated shatavari preparations therefore cannot establish the behaviour of the complete formula, nor can a matching ingredient amount substitute for a finished-product study.
The most defensible reading is concise: the label confirms Asparagus racemosus root extract at 100 mg per two capsules; recent human research examines several defined shatavari extracts; and the visible information does not establish that Vitalux Women contains any of those proprietary study materials.
“A botanical name identifies the plant. Extract ratio, marker chemistry, assay and dose identify the material that was actually studied.”
Explore Vitalux Women with BioEssentials
Review the active Vitalux Women page for its complete serving, botanical amounts and important-use information. If extract standardisation is central to your decision, ask for the current supplier specification rather than inferring it from milligrams alone.
Explore the verified Vitalux Women product page
Frequently Asked Questions
How much shatavari is listed in Vitalux Women?
The verified France label lists 100 mg of Asparagus racemosus root extract in the two-capsule daily serving.
Is Vitalux Women's 100 mg shatavari the same as the 100 mg extract in a human study?
That identity is not established. The study used a proprietary hydroethanolic extract standardised to Shatavarin IV, while the active Vitalux Women page does not state an extract ratio or shatavarin specification.
What are shatavarins?
Shatavarins are steroidal saponins used as chemical markers for shatavari extracts. A marker percentage and its analytical method help define what was actually studied.
Why are the three shatavari studies not interchangeable?
They used different named extracts, daily doses, marker specifications, analytical methods and participant populations, so their findings belong to those study materials rather than every shatavari product.
How is Vitalux Women taken?
The active page states two capsules per day with water, for adults, and advises consultation when medication or a health condition is involved. The label does not recommend use during pregnancy or breastfeeding.
Recommended
- Vitalux Women: a label-first guide to its botanical and micronutrient matrix
- Fenugreek extract: why standardisation and dose shape the evidence
- Tribulus in Vitalux Men: saponins, standardisation and evidence boundaries
- Selenium in SperBalan: selenoproteins and normal spermatogenesis
- How to choose supplements with a label-first framework
Our research and formulas have been recognized by leading media outlets such as Marie Claire.
Scientific References
- A 60-participant placebo-controlled study of a 100 mg SheVari4 shatavari extract
- A 70-participant multicentre study of 500 mg/day Aspurus shatavari extract
- An 80-participant study of a 300 mg, 13:1 shatavari extract standardised to more than 10% total shatavarins
These statements have not been evaluated by the Food and Drug Administration. BioEssentials products are food supplements intended to support general wellness and daily nutritional needs. They are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any new supplement if you are pregnant, breastfeeding, taking medication, or managing a health condition.
